INVST’s Definium Therapeutics DFTX Stock Holding History

INVST’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,071	Closed	-$37K	–	205
2021 Q3	$37K	Hold	1,071	–	–	0.01%	194
2021 Q2	$51K	Buy	+1,071	New	+$56.2K	0.01%	193

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

INVST's DFTX Position: Q4 2021 in Review

INVST sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 1,071 shares — an estimated $37K sold.

INVST first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $51K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

INVST reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
INVST sold 1,071 Definium Therapeutics shares in Q4 2021, an estimated $37K.
INVST first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
INVST's Definium Therapeutics position peaked at $51K in Q2 2021.
176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on INVST's 13F filing for Q4 2021, filed 25 Feb 2022.